Lv4
460 积分 2024-09-27 加入
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
10天前
已完结
Prescribing semaglutide for weight loss in non-diabetic, obese patients is associated with an increased risk of erectile dysfunction: a TriNetX database study
10天前
已完结
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
10天前
已完结
Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial
10天前
已完结
中国肥胖及2型糖尿病外科治疗指南（2019版）
22天前
已完结
Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
25天前
已完结
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
25天前
已完结
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
2个月前
已完结
Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial
2个月前
已完结
Urine Albumin-Creatinine Ratio Variability in People With Type 2 Diabetes: Clinical and Research Implications
2个月前
已完结
皖公网安备34019202002308
